1
|
Aung N, Bartoli A, Rauseo E, Cortaredona S, Sanghvi MM, Fournel J, Ghattas B, Khanji MY, Petersen SE, Jacquier A. Left Ventricular Trabeculations at Cardiac MRI: Reference Ranges and Association with Cardiovascular Risk Factors in UK Biobank. Radiology 2024; 311:e232455. [PMID: 38563665 DOI: 10.1148/radiol.232455] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2024]
Abstract
Background The extent of left ventricular (LV) trabeculation and its relationship with cardiovascular (CV) risk factors is unclear. Purpose To apply automated segmentation to UK Biobank cardiac MRI scans to (a) assess the association between individual characteristics and CV risk factors and trabeculated LV mass (LVM) and (b) establish normal reference ranges in a selected group of healthy UK Biobank participants. Materials and Methods In this cross-sectional secondary analysis, prospectively collected data from the UK Biobank (2006 to 2010) were retrospectively analyzed. Automated segmentation of trabeculations was performed using a deep learning algorithm. After excluding individuals with known CV diseases, White adults without CV risk factors (reference group) and those with preexisting CV risk factors (hypertension, hyperlipidemia, diabetes mellitus, or smoking) (exposed group) were compared. Multivariable regression models, adjusted for potential confounders (age, sex, and height), were fitted to evaluate the associations between individual characteristics and CV risk factors and trabeculated LVM. Results Of 43 038 participants (mean age, 64 years ± 8 [SD]; 22 360 women), 28 672 individuals (mean age, 66 years ± 7; 14 918 men) were included in the exposed group, and 7384 individuals (mean age, 60 years ± 7; 4729 women) were included in the reference group. Higher body mass index (BMI) (β = 0.66 [95% CI: 0.63, 0.68]; P < .001), hypertension (β = 0.42 [95% CI: 0.36, 0.48]; P < .001), and higher physical activity level (β = 0.15 [95% CI: 0.12, 0.17]; P < .001) were associated with higher trabeculated LVM. In the reference group, the median trabeculated LVM was 6.3 g (IQR, 4.7-8.5 g) for men and 4.6 g (IQR, 3.4-6.0 g) for women. Median trabeculated LVM decreased with age for men from 6.5 g (IQR, 4.8-8.7 g) at age 45-50 years to 5.9 g (IQR, 4.3-7.8 g) at age 71-80 years (P = .03). Conclusion Higher trabeculated LVM was observed with hypertension, higher BMI, and higher physical activity level. Age- and sex-specific reference ranges of trabeculated LVM in a healthy middle-aged White population were established. © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Kawel-Boehm in this issue.
Collapse
Affiliation(s)
- Nay Aung
- From the Centre for Advanced Cardiovascular Imaging, William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, London, England (N.A., E.R., M.M.S., M.Y.K., S.E.P.); Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, England (N.A., E.R., M.M.S., M.Y.K., S.E.P.); Department of Radiology, Hôpital de la Timone, AP-HM, 264 rue Saint-Pierre, 13385 Marseille CEDEX 05, France (A.B., A.J.); Center for Magnetic Resonance in Biology and Medicine, UMR CNRS 7339, Aix-Marseille University, Marseille, France (A.B., J.F., A.J.); Institut de Recherche pour le Developpement, VITROME, Aix-Marseille University, Marseille, France (S.C.); Aix-Marseille School of Economics, Aix-Marseille University, Marseille, France (B.G.); Newham University Hospital, Barts Health NHS Trust, London, England (M.Y.K.); Health Data Research UK, London, England (S.E.P.); and Alan Turing Institute, London, England (S.E.P.)
| | - Axel Bartoli
- From the Centre for Advanced Cardiovascular Imaging, William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, London, England (N.A., E.R., M.M.S., M.Y.K., S.E.P.); Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, England (N.A., E.R., M.M.S., M.Y.K., S.E.P.); Department of Radiology, Hôpital de la Timone, AP-HM, 264 rue Saint-Pierre, 13385 Marseille CEDEX 05, France (A.B., A.J.); Center for Magnetic Resonance in Biology and Medicine, UMR CNRS 7339, Aix-Marseille University, Marseille, France (A.B., J.F., A.J.); Institut de Recherche pour le Developpement, VITROME, Aix-Marseille University, Marseille, France (S.C.); Aix-Marseille School of Economics, Aix-Marseille University, Marseille, France (B.G.); Newham University Hospital, Barts Health NHS Trust, London, England (M.Y.K.); Health Data Research UK, London, England (S.E.P.); and Alan Turing Institute, London, England (S.E.P.)
| | - Elisa Rauseo
- From the Centre for Advanced Cardiovascular Imaging, William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, London, England (N.A., E.R., M.M.S., M.Y.K., S.E.P.); Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, England (N.A., E.R., M.M.S., M.Y.K., S.E.P.); Department of Radiology, Hôpital de la Timone, AP-HM, 264 rue Saint-Pierre, 13385 Marseille CEDEX 05, France (A.B., A.J.); Center for Magnetic Resonance in Biology and Medicine, UMR CNRS 7339, Aix-Marseille University, Marseille, France (A.B., J.F., A.J.); Institut de Recherche pour le Developpement, VITROME, Aix-Marseille University, Marseille, France (S.C.); Aix-Marseille School of Economics, Aix-Marseille University, Marseille, France (B.G.); Newham University Hospital, Barts Health NHS Trust, London, England (M.Y.K.); Health Data Research UK, London, England (S.E.P.); and Alan Turing Institute, London, England (S.E.P.)
| | - Sebastien Cortaredona
- From the Centre for Advanced Cardiovascular Imaging, William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, London, England (N.A., E.R., M.M.S., M.Y.K., S.E.P.); Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, England (N.A., E.R., M.M.S., M.Y.K., S.E.P.); Department of Radiology, Hôpital de la Timone, AP-HM, 264 rue Saint-Pierre, 13385 Marseille CEDEX 05, France (A.B., A.J.); Center for Magnetic Resonance in Biology and Medicine, UMR CNRS 7339, Aix-Marseille University, Marseille, France (A.B., J.F., A.J.); Institut de Recherche pour le Developpement, VITROME, Aix-Marseille University, Marseille, France (S.C.); Aix-Marseille School of Economics, Aix-Marseille University, Marseille, France (B.G.); Newham University Hospital, Barts Health NHS Trust, London, England (M.Y.K.); Health Data Research UK, London, England (S.E.P.); and Alan Turing Institute, London, England (S.E.P.)
| | - Mihir M Sanghvi
- From the Centre for Advanced Cardiovascular Imaging, William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, London, England (N.A., E.R., M.M.S., M.Y.K., S.E.P.); Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, England (N.A., E.R., M.M.S., M.Y.K., S.E.P.); Department of Radiology, Hôpital de la Timone, AP-HM, 264 rue Saint-Pierre, 13385 Marseille CEDEX 05, France (A.B., A.J.); Center for Magnetic Resonance in Biology and Medicine, UMR CNRS 7339, Aix-Marseille University, Marseille, France (A.B., J.F., A.J.); Institut de Recherche pour le Developpement, VITROME, Aix-Marseille University, Marseille, France (S.C.); Aix-Marseille School of Economics, Aix-Marseille University, Marseille, France (B.G.); Newham University Hospital, Barts Health NHS Trust, London, England (M.Y.K.); Health Data Research UK, London, England (S.E.P.); and Alan Turing Institute, London, England (S.E.P.)
| | - Joris Fournel
- From the Centre for Advanced Cardiovascular Imaging, William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, London, England (N.A., E.R., M.M.S., M.Y.K., S.E.P.); Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, England (N.A., E.R., M.M.S., M.Y.K., S.E.P.); Department of Radiology, Hôpital de la Timone, AP-HM, 264 rue Saint-Pierre, 13385 Marseille CEDEX 05, France (A.B., A.J.); Center for Magnetic Resonance in Biology and Medicine, UMR CNRS 7339, Aix-Marseille University, Marseille, France (A.B., J.F., A.J.); Institut de Recherche pour le Developpement, VITROME, Aix-Marseille University, Marseille, France (S.C.); Aix-Marseille School of Economics, Aix-Marseille University, Marseille, France (B.G.); Newham University Hospital, Barts Health NHS Trust, London, England (M.Y.K.); Health Data Research UK, London, England (S.E.P.); and Alan Turing Institute, London, England (S.E.P.)
| | - Badih Ghattas
- From the Centre for Advanced Cardiovascular Imaging, William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, London, England (N.A., E.R., M.M.S., M.Y.K., S.E.P.); Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, England (N.A., E.R., M.M.S., M.Y.K., S.E.P.); Department of Radiology, Hôpital de la Timone, AP-HM, 264 rue Saint-Pierre, 13385 Marseille CEDEX 05, France (A.B., A.J.); Center for Magnetic Resonance in Biology and Medicine, UMR CNRS 7339, Aix-Marseille University, Marseille, France (A.B., J.F., A.J.); Institut de Recherche pour le Developpement, VITROME, Aix-Marseille University, Marseille, France (S.C.); Aix-Marseille School of Economics, Aix-Marseille University, Marseille, France (B.G.); Newham University Hospital, Barts Health NHS Trust, London, England (M.Y.K.); Health Data Research UK, London, England (S.E.P.); and Alan Turing Institute, London, England (S.E.P.)
| | - Mohammed Y Khanji
- From the Centre for Advanced Cardiovascular Imaging, William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, London, England (N.A., E.R., M.M.S., M.Y.K., S.E.P.); Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, England (N.A., E.R., M.M.S., M.Y.K., S.E.P.); Department of Radiology, Hôpital de la Timone, AP-HM, 264 rue Saint-Pierre, 13385 Marseille CEDEX 05, France (A.B., A.J.); Center for Magnetic Resonance in Biology and Medicine, UMR CNRS 7339, Aix-Marseille University, Marseille, France (A.B., J.F., A.J.); Institut de Recherche pour le Developpement, VITROME, Aix-Marseille University, Marseille, France (S.C.); Aix-Marseille School of Economics, Aix-Marseille University, Marseille, France (B.G.); Newham University Hospital, Barts Health NHS Trust, London, England (M.Y.K.); Health Data Research UK, London, England (S.E.P.); and Alan Turing Institute, London, England (S.E.P.)
| | - Steffen E Petersen
- From the Centre for Advanced Cardiovascular Imaging, William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, London, England (N.A., E.R., M.M.S., M.Y.K., S.E.P.); Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, England (N.A., E.R., M.M.S., M.Y.K., S.E.P.); Department of Radiology, Hôpital de la Timone, AP-HM, 264 rue Saint-Pierre, 13385 Marseille CEDEX 05, France (A.B., A.J.); Center for Magnetic Resonance in Biology and Medicine, UMR CNRS 7339, Aix-Marseille University, Marseille, France (A.B., J.F., A.J.); Institut de Recherche pour le Developpement, VITROME, Aix-Marseille University, Marseille, France (S.C.); Aix-Marseille School of Economics, Aix-Marseille University, Marseille, France (B.G.); Newham University Hospital, Barts Health NHS Trust, London, England (M.Y.K.); Health Data Research UK, London, England (S.E.P.); and Alan Turing Institute, London, England (S.E.P.)
| | - Alexis Jacquier
- From the Centre for Advanced Cardiovascular Imaging, William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, London, England (N.A., E.R., M.M.S., M.Y.K., S.E.P.); Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, England (N.A., E.R., M.M.S., M.Y.K., S.E.P.); Department of Radiology, Hôpital de la Timone, AP-HM, 264 rue Saint-Pierre, 13385 Marseille CEDEX 05, France (A.B., A.J.); Center for Magnetic Resonance in Biology and Medicine, UMR CNRS 7339, Aix-Marseille University, Marseille, France (A.B., J.F., A.J.); Institut de Recherche pour le Developpement, VITROME, Aix-Marseille University, Marseille, France (S.C.); Aix-Marseille School of Economics, Aix-Marseille University, Marseille, France (B.G.); Newham University Hospital, Barts Health NHS Trust, London, England (M.Y.K.); Health Data Research UK, London, England (S.E.P.); and Alan Turing Institute, London, England (S.E.P.)
| |
Collapse
|
2
|
Meshkov AN, Myasnikov RP, Kiseleva AV, Kulikova OV, Sotnikova EA, Kudryavtseva MM, Zharikova AA, Koretskiy SN, Mershina EA, Ramensky VE, Zaicenoka M, Vyatkin YV, Kharlap MS, Nikityuk TG, Sinitsyn VE, Divashuk MG, Kutsenko VA, Basargina EN, Barskiy VI, Sdvigova NA, Skirko OP, Efimova IA, Pokrovskaya MS, Drapkina OM. Genetic landscape in Russian patients with familial left ventricular noncompaction. Front Cardiovasc Med 2023; 10:1205787. [PMID: 37342443 PMCID: PMC10278580 DOI: 10.3389/fcvm.2023.1205787] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2023] [Accepted: 05/09/2023] [Indexed: 06/22/2023] Open
Abstract
Background Left ventricular noncompaction (LVNC) cardiomyopathy is a disorder that can be complicated by heart failure, arrhythmias, thromboembolism, and sudden cardiac death. The aim of this study is to clarify the genetic landscape of LVNC in a large cohort of well-phenotyped Russian patients with LVNC, including 48 families (n=214). Methods All index patients underwent clinical examination and genetic analysis, as well as family members who agreed to participate in the clinical study and/or in the genetic testing. The genetic testing included next generation sequencing and genetic classification according to ACMG guidelines. Results A total of 55 alleles of 54 pathogenic and likely pathogenic variants in 24 genes were identified, with the largest number in the MYH7 and TTN genes. A significant proportion of variants -8 of 54 (14.8%) -have not been described earlier in other populations and may be specific to LVNC patients in Russia. In LVNC patients, the presence of each subsequent variant is associated with increased odds of having more severe LVNC subtypes than isolated LVNC with preserved ejection fraction. The corresponding odds ratio is 2.77 (1.37 -7.37; p <0.001) per variant after adjustment for sex, age, and family. Conclusion Overall, the genetic analysis of LVNC patients, accompanied by cardiomyopathy-related family history analysis, resulted in a high diagnostic yield of 89.6%. These results suggest that genetic screening should be applied to the diagnosis and prognosis of LVNC patients.
Collapse
Affiliation(s)
- Alexey N. Meshkov
- National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of the Russian Federation, Moscow, Russia
- National Medical Research Center for Cardiology of the Ministry of Healthcare of the Russian Federation, Moscow, Russia
- Hereditary Metabolic Diseases Laboratory, Research Centre for Medical Genetics, Moscow, Russia
- Department of General and Medical Genetics, Pirogov Russian National Research Medical University, Moscow, Russia
| | - Roman P. Myasnikov
- National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of the Russian Federation, Moscow, Russia
| | - Anna V. Kiseleva
- National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of the Russian Federation, Moscow, Russia
| | - Olga V. Kulikova
- National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of the Russian Federation, Moscow, Russia
| | - Evgeniia A. Sotnikova
- National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of the Russian Federation, Moscow, Russia
| | - Maria M. Kudryavtseva
- National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of the Russian Federation, Moscow, Russia
| | - Anastasia A. Zharikova
- National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of the Russian Federation, Moscow, Russia
- Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow, Russia
| | - Sergey N. Koretskiy
- National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of the Russian Federation, Moscow, Russia
| | - Elena A. Mershina
- Medical Research and Educational Center, Lomonosov Moscow State University, Moscow, Russia
| | - Vasily E. Ramensky
- National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of the Russian Federation, Moscow, Russia
- Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow, Russia
| | - Marija Zaicenoka
- Phystech School of Biological and Medical Physics, Moscow Institute of Physics and Technology, Dolgoprudny, Russia
| | - Yuri V. Vyatkin
- National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of the Russian Federation, Moscow, Russia
- Department of Natural Sciences, Novosibirsk State University, Novosibirsk, Russia
| | - Maria S. Kharlap
- National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of the Russian Federation, Moscow, Russia
| | - Tatiana G. Nikityuk
- National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of the Russian Federation, Moscow, Russia
| | - Valentin E. Sinitsyn
- Medical Research and Educational Center, Lomonosov Moscow State University, Moscow, Russia
| | - Mikhail G. Divashuk
- National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of the Russian Federation, Moscow, Russia
- Laboratory of Applied Genomics and Crop Breeding, All-Russia Research Institute of Agricultural Biotechnology, Moscow, Russia
| | - Vladimir A. Kutsenko
- National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of the Russian Federation, Moscow, Russia
- Faculty of Mechanics and Mathematics, Lomonosov Moscow State University, Moscow, Russia
| | | | | | | | - Olga P. Skirko
- National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of the Russian Federation, Moscow, Russia
| | - Irina A. Efimova
- National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of the Russian Federation, Moscow, Russia
| | - Maria S. Pokrovskaya
- National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of the Russian Federation, Moscow, Russia
| | - Oxana M. Drapkina
- National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of the Russian Federation, Moscow, Russia
| |
Collapse
|
3
|
Myasnikov R, Brodehl A, Meshkov A, Kulikova O, Kiseleva A, Pohl GM, Sotnikova E, Divashuk M, Klimushina M, Zharikova A, Pokrovskaya M, Koretskiy S, Kharlap M, Mershina E, Sinitsyn V, Basargina E, Gandaeva L, Barskiy V, Boytsov S, Milting H, Drapkina O. The Double Mutation DSG2-p.S363X and TBX20-p.D278X Is Associated with Left Ventricular Non-Compaction Cardiomyopathy: Case Report. Int J Mol Sci 2021; 22:ijms22136775. [PMID: 34202524 PMCID: PMC8268202 DOI: 10.3390/ijms22136775] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Revised: 06/10/2021] [Accepted: 06/22/2021] [Indexed: 12/12/2022] Open
Abstract
Left ventricular non-compaction cardiomyopathy (LVNC) is a rare heart disease, with or without left ventricular dysfunction, which is characterized by a two-layer structure of the myocardium and an increased number of trabeculae. The study of familial forms of LVNC is helpful for risk prediction and genetic counseling of relatives. Here, we present a family consisting of three members with LVNC. Using a next-generation sequencing approach a combination of two (likely) pathogenic nonsense mutations DSG2-p.S363X and TBX20-p.D278X was identified in all three patients. TBX20 encodes the cardiac T-box transcription factor 20. DSG2 encodes desmoglein–2, which is part of the cardiac desmosomes and belongs to the cadherin family. Since the identified nonsense variant (DSG2-p.S363X) is localized in the extracellular domain of DSG2, we performed in vitro cell transfection experiments. These experiments revealed the absence of truncated DSG2 at the plasma membrane, supporting the pathogenic relevance of DSG2-p.S363X. In conclusion, we suggest that in the future, these findings might be helpful for genetic screening and counseling of patients with LVNC.
Collapse
Affiliation(s)
- Roman Myasnikov
- National Research Center for Therapy and Preventive Medicine, Petroverigskiy Lane 10, 101990 Moscow, Russia; (R.M.); (A.M.); (O.K.); (E.S.); (M.D.); (M.K.); (A.Z.); (M.P.); (S.K.); (M.K.); (O.D.)
| | - Andreas Brodehl
- Erich and Hanna Klessmann Institute, Heart and Diabetes Center NRW, University Hospital of the Ruhr-University Bochum, Georgstrasse 11, 32545 Bad Oeynhausen, Germany; (G.M.P.); (H.M.)
- Correspondence: (A.B.); (A.K.)
| | - Alexey Meshkov
- National Research Center for Therapy and Preventive Medicine, Petroverigskiy Lane 10, 101990 Moscow, Russia; (R.M.); (A.M.); (O.K.); (E.S.); (M.D.); (M.K.); (A.Z.); (M.P.); (S.K.); (M.K.); (O.D.)
| | - Olga Kulikova
- National Research Center for Therapy and Preventive Medicine, Petroverigskiy Lane 10, 101990 Moscow, Russia; (R.M.); (A.M.); (O.K.); (E.S.); (M.D.); (M.K.); (A.Z.); (M.P.); (S.K.); (M.K.); (O.D.)
| | - Anna Kiseleva
- National Research Center for Therapy and Preventive Medicine, Petroverigskiy Lane 10, 101990 Moscow, Russia; (R.M.); (A.M.); (O.K.); (E.S.); (M.D.); (M.K.); (A.Z.); (M.P.); (S.K.); (M.K.); (O.D.)
- Correspondence: (A.B.); (A.K.)
| | - Greta Marie Pohl
- Erich and Hanna Klessmann Institute, Heart and Diabetes Center NRW, University Hospital of the Ruhr-University Bochum, Georgstrasse 11, 32545 Bad Oeynhausen, Germany; (G.M.P.); (H.M.)
| | - Evgeniia Sotnikova
- National Research Center for Therapy and Preventive Medicine, Petroverigskiy Lane 10, 101990 Moscow, Russia; (R.M.); (A.M.); (O.K.); (E.S.); (M.D.); (M.K.); (A.Z.); (M.P.); (S.K.); (M.K.); (O.D.)
| | - Mikhail Divashuk
- National Research Center for Therapy and Preventive Medicine, Petroverigskiy Lane 10, 101990 Moscow, Russia; (R.M.); (A.M.); (O.K.); (E.S.); (M.D.); (M.K.); (A.Z.); (M.P.); (S.K.); (M.K.); (O.D.)
- All-Russia Research Institute of Agricultural Biotechnology, Timiryazevskaya Street, 42, 127550 Moscow, Russia
| | - Marina Klimushina
- National Research Center for Therapy and Preventive Medicine, Petroverigskiy Lane 10, 101990 Moscow, Russia; (R.M.); (A.M.); (O.K.); (E.S.); (M.D.); (M.K.); (A.Z.); (M.P.); (S.K.); (M.K.); (O.D.)
| | - Anastasia Zharikova
- National Research Center for Therapy and Preventive Medicine, Petroverigskiy Lane 10, 101990 Moscow, Russia; (R.M.); (A.M.); (O.K.); (E.S.); (M.D.); (M.K.); (A.Z.); (M.P.); (S.K.); (M.K.); (O.D.)
- Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Lomonosovsky Prospect 27, Building 10, 119991 Moscow, Russia
| | - Maria Pokrovskaya
- National Research Center for Therapy and Preventive Medicine, Petroverigskiy Lane 10, 101990 Moscow, Russia; (R.M.); (A.M.); (O.K.); (E.S.); (M.D.); (M.K.); (A.Z.); (M.P.); (S.K.); (M.K.); (O.D.)
| | - Sergey Koretskiy
- National Research Center for Therapy and Preventive Medicine, Petroverigskiy Lane 10, 101990 Moscow, Russia; (R.M.); (A.M.); (O.K.); (E.S.); (M.D.); (M.K.); (A.Z.); (M.P.); (S.K.); (M.K.); (O.D.)
| | - Maria Kharlap
- National Research Center for Therapy and Preventive Medicine, Petroverigskiy Lane 10, 101990 Moscow, Russia; (R.M.); (A.M.); (O.K.); (E.S.); (M.D.); (M.K.); (A.Z.); (M.P.); (S.K.); (M.K.); (O.D.)
| | - Elena Mershina
- Medical Research and Educational Center, Lomonosov Moscow State University, Lomonosovsky Prospect 27, Building 10, 119991 Moscow, Russia; (E.M.); (V.S.)
| | - Valentin Sinitsyn
- Medical Research and Educational Center, Lomonosov Moscow State University, Lomonosovsky Prospect 27, Building 10, 119991 Moscow, Russia; (E.M.); (V.S.)
| | - Elena Basargina
- National Medical Research Center for Children’s Health, Lomonosovsky Prospect 2, Building 1, 119991 Moscow, Russia; (E.B.); (L.G.); (V.B.)
| | - Leila Gandaeva
- National Medical Research Center for Children’s Health, Lomonosovsky Prospect 2, Building 1, 119991 Moscow, Russia; (E.B.); (L.G.); (V.B.)
| | - Vladimir Barskiy
- National Medical Research Center for Children’s Health, Lomonosovsky Prospect 2, Building 1, 119991 Moscow, Russia; (E.B.); (L.G.); (V.B.)
| | - Sergey Boytsov
- National Medical Research Center for Cardiology, 3-ya Cherepkovskaya Street, 15A, 121552 Moscow, Russia;
| | - Hendrik Milting
- Erich and Hanna Klessmann Institute, Heart and Diabetes Center NRW, University Hospital of the Ruhr-University Bochum, Georgstrasse 11, 32545 Bad Oeynhausen, Germany; (G.M.P.); (H.M.)
| | - Oxana Drapkina
- National Research Center for Therapy and Preventive Medicine, Petroverigskiy Lane 10, 101990 Moscow, Russia; (R.M.); (A.M.); (O.K.); (E.S.); (M.D.); (M.K.); (A.Z.); (M.P.); (S.K.); (M.K.); (O.D.)
| |
Collapse
|
4
|
Stöllberger C, Finsterer J. Correlation between pathoanatomic findings, imaging modalities, and genetic findings in patients with left ventricular hypertrabeculation/noncompaction. Expert Rev Cardiovasc Ther 2021; 19:595-606. [PMID: 34053374 DOI: 10.1080/14779072.2021.1937128] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Introduction: Left ventricular hypertrabeculation, also named 'noncompaction' (LVHT) is a cardiac abnormality which is detected by pathoanatomic investigation or during cardiac surgery. Imaging techniques visualize LVHT by ventriculography, echocardiography, cardiac magnetic resonance imaging (CMRI) and computed tomography (CT).Areas covered: We aimed to assess 1) how often the definition of LVHT was validated against a criterion standard, 2) if inter- and intra-observer agreement was assessed, and 3) how often LVHT was associated with genetic diseases. A literature search disclosed 58 cases whose hearts were investigated pathoanatomically and by ≥1 imaging technique. Echocardiography was most frequently (95%) compared with pathoanatomy, followed by cMRI (31%), ventriculography (7%) and CT (5%). Intra- and inter-observer agreement was more frequently assessed for cMRI definitions and yielded more consistent results than for echocardiographic definitions. Since genetic findings were only reported from 4 of the 58 cases, no association with imaging findings could be carried out.Expert opinion: Correlation between pathoanatomic investigations with imaging techniques will hopefully contribute to reliable and uniformly accepted definitions of LVHT. Most probably, the echocardiographic definition of LVHT will be a synthesis of the currently used definitions, integrating short axis and four-chamber views. A refinement of cMRI definitions, considering pathoanatomic and echocardiographic investigations, seems necessary to avoid overdiagnosis.
Collapse
|
5
|
Gerecke BJ, Engberding R. Noncompaction Cardiomyopathy-History and Current Knowledge for Clinical Practice. J Clin Med 2021; 10:2457. [PMID: 34206037 PMCID: PMC8199228 DOI: 10.3390/jcm10112457] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2021] [Revised: 05/24/2021] [Accepted: 05/27/2021] [Indexed: 01/10/2023] Open
Abstract
Noncompaction cardiomyopathy (NCCM) has gained increasing attention over the past twenty years, but in daily clinical practice NCCM is still rarely considered. So far, there are no generally accepted diagnostic criteria and some groups even refuse to acknowledge it as a distinct cardiomyopathy, and grade it as a variant of dilated cardiomyopathy or a morphological trait of different conditions. A wide range of morphological variants have been observed even in healthy persons, suggesting that pathologic remodeling and physiologic adaptation have to be differentiated in cases where this spongy myocardial pattern is encountered. Recent studies have uncovered numerous new pathogenetic and pathophysiologic aspects of this elusive cardiomyopathy, but a current summary and evaluation of clinical patient management are still lacking, especially to avoid mis- and overdiagnosis. Addressing this issue, this article provides an up to date overview of the current knowledge in classification, pathogenesis, pathophysiology, epidemiology, clinical manifestations and diagnostic evaluation, including genetic testing, treatment and prognosis of NCCM.
Collapse
Affiliation(s)
- Birgit J. Gerecke
- Department of Cardiology and Pneumology, University Medical Center Göttingen, 37075 Göttingen, Germany
- Department of Thoracic and Cardiovascular Surgery, University Medical Center Göttingen, 37075 Göttingen, Germany
| | - Rolf Engberding
- Internal Medicine & Cardiology, amO MVZ, Academic Hospital Wolfsburg, 38440 Wolfsburg, Germany;
| |
Collapse
|
6
|
Bartoli A, Fournel J, Bentatou Z, Habib G, Lalande A, Bernard M, Boussel L, Pontana F, Dacher JN, Ghattas B, Jacquier A. Deep Learning-based Automated Segmentation of Left Ventricular Trabeculations and Myocardium on Cardiac MR Images: A Feasibility Study. Radiol Artif Intell 2021; 3:e200021. [PMID: 33937851 DOI: 10.1148/ryai.2020200021] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2020] [Revised: 08/16/2020] [Accepted: 09/16/2020] [Indexed: 01/25/2023]
Abstract
Purpose To develop and evaluate a complete deep learning pipeline that allows fully automated end-diastolic left ventricle (LV) cardiac MRI segmentation, including trabeculations and automatic quality control of the predicted segmentation. Materials and Methods This multicenter retrospective study includes training, validation, and testing datasets of 272, 27, and 150 cardiac MR images, respectively, collected between 2012 and 2018. The reference standard was the manual segmentation of four LV anatomic structures performed on end-diastolic short-axis cine cardiac MRI: LV trabeculations, LV myocardium, LV papillary muscles, and the LV blood cavity. The automatic pipeline was composed of five steps with a DenseNet architecture. Intraobserver agreement, interobserver agreement, and interaction time were recorded. The analysis includes the correlation between the manual and automated segmentation, a reproducibility comparison, and Bland-Altman plots. Results The automated method achieved mean Dice coefficients of 0.96 ± 0.01 (standard deviation) for LV blood cavity, 0.89 ± 0.03 for LV myocardium, and 0.62 ± 0.08 for LV trabeculation (mean absolute error, 3.63 g ± 3.4). Automatic quantification of LV end-diastolic volume, LV myocardium mass, LV trabeculation, and trabeculation mass-to-total myocardial mass (TMM) ratio showed a significant correlation with the manual measures (r = 0.99, 0.99, 0.90, and 0.83, respectively; all P < .01). On a subset of 48 patients, the mean Dice value for LV trabeculation was 0.63 ± 0.10 or higher compared with the human interobserver (0.44 ± 0.09; P < .01) and intraobserver measures (0.58 ± 0.09; P < .01). Automatic quantification of the trabeculation mass-to-TMM ratio had a higher correlation (0.92) compared with the intra- and interobserver measures (0.74 and 0.39, respectively; both P < .01). Conclusion Automated deep learning framework can achieve reproducible and quality-controlled segmentation of cardiac trabeculations, outperforming inter- and intraobserver analyses.Supplemental material is available for this article.© RSNA, 2020.
Collapse
Affiliation(s)
- Axel Bartoli
- Departments of Radiology (A.B., A.J.) and Cardiology (G.H.), Hôpital de la Timone Adultes, AP-HM, 264, rue Saint-Pierre 13385 Marseille Cedex 05, France; CRMBM-UMR CNRS 7339, Medical Faculty, Aix-Marseille University, Marseille, France (A.B., J.F., Z.B., M.B., A.J.); I2M-UMR CNRS 7373, Aix-Marseille University, Centrale Marseille, Marseille, France (J.F., B.G.); ImVia Laboratory and University Hospital of Dijon, Bourgogne-Franche Comté University, Dijon, France (A.L.); Department of Radiology, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France (L.B.); Department of Cardiovascular Imaging, Lille University Hospital, Lille, France (F.P.); and Department of Diagnostic Imaging, Rouen University Hospital, Rouen, France (J.N.D.)
| | - Joris Fournel
- Departments of Radiology (A.B., A.J.) and Cardiology (G.H.), Hôpital de la Timone Adultes, AP-HM, 264, rue Saint-Pierre 13385 Marseille Cedex 05, France; CRMBM-UMR CNRS 7339, Medical Faculty, Aix-Marseille University, Marseille, France (A.B., J.F., Z.B., M.B., A.J.); I2M-UMR CNRS 7373, Aix-Marseille University, Centrale Marseille, Marseille, France (J.F., B.G.); ImVia Laboratory and University Hospital of Dijon, Bourgogne-Franche Comté University, Dijon, France (A.L.); Department of Radiology, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France (L.B.); Department of Cardiovascular Imaging, Lille University Hospital, Lille, France (F.P.); and Department of Diagnostic Imaging, Rouen University Hospital, Rouen, France (J.N.D.)
| | - Zakarya Bentatou
- Departments of Radiology (A.B., A.J.) and Cardiology (G.H.), Hôpital de la Timone Adultes, AP-HM, 264, rue Saint-Pierre 13385 Marseille Cedex 05, France; CRMBM-UMR CNRS 7339, Medical Faculty, Aix-Marseille University, Marseille, France (A.B., J.F., Z.B., M.B., A.J.); I2M-UMR CNRS 7373, Aix-Marseille University, Centrale Marseille, Marseille, France (J.F., B.G.); ImVia Laboratory and University Hospital of Dijon, Bourgogne-Franche Comté University, Dijon, France (A.L.); Department of Radiology, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France (L.B.); Department of Cardiovascular Imaging, Lille University Hospital, Lille, France (F.P.); and Department of Diagnostic Imaging, Rouen University Hospital, Rouen, France (J.N.D.)
| | - Gilbert Habib
- Departments of Radiology (A.B., A.J.) and Cardiology (G.H.), Hôpital de la Timone Adultes, AP-HM, 264, rue Saint-Pierre 13385 Marseille Cedex 05, France; CRMBM-UMR CNRS 7339, Medical Faculty, Aix-Marseille University, Marseille, France (A.B., J.F., Z.B., M.B., A.J.); I2M-UMR CNRS 7373, Aix-Marseille University, Centrale Marseille, Marseille, France (J.F., B.G.); ImVia Laboratory and University Hospital of Dijon, Bourgogne-Franche Comté University, Dijon, France (A.L.); Department of Radiology, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France (L.B.); Department of Cardiovascular Imaging, Lille University Hospital, Lille, France (F.P.); and Department of Diagnostic Imaging, Rouen University Hospital, Rouen, France (J.N.D.)
| | - Alain Lalande
- Departments of Radiology (A.B., A.J.) and Cardiology (G.H.), Hôpital de la Timone Adultes, AP-HM, 264, rue Saint-Pierre 13385 Marseille Cedex 05, France; CRMBM-UMR CNRS 7339, Medical Faculty, Aix-Marseille University, Marseille, France (A.B., J.F., Z.B., M.B., A.J.); I2M-UMR CNRS 7373, Aix-Marseille University, Centrale Marseille, Marseille, France (J.F., B.G.); ImVia Laboratory and University Hospital of Dijon, Bourgogne-Franche Comté University, Dijon, France (A.L.); Department of Radiology, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France (L.B.); Department of Cardiovascular Imaging, Lille University Hospital, Lille, France (F.P.); and Department of Diagnostic Imaging, Rouen University Hospital, Rouen, France (J.N.D.)
| | - Monique Bernard
- Departments of Radiology (A.B., A.J.) and Cardiology (G.H.), Hôpital de la Timone Adultes, AP-HM, 264, rue Saint-Pierre 13385 Marseille Cedex 05, France; CRMBM-UMR CNRS 7339, Medical Faculty, Aix-Marseille University, Marseille, France (A.B., J.F., Z.B., M.B., A.J.); I2M-UMR CNRS 7373, Aix-Marseille University, Centrale Marseille, Marseille, France (J.F., B.G.); ImVia Laboratory and University Hospital of Dijon, Bourgogne-Franche Comté University, Dijon, France (A.L.); Department of Radiology, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France (L.B.); Department of Cardiovascular Imaging, Lille University Hospital, Lille, France (F.P.); and Department of Diagnostic Imaging, Rouen University Hospital, Rouen, France (J.N.D.)
| | - Loïc Boussel
- Departments of Radiology (A.B., A.J.) and Cardiology (G.H.), Hôpital de la Timone Adultes, AP-HM, 264, rue Saint-Pierre 13385 Marseille Cedex 05, France; CRMBM-UMR CNRS 7339, Medical Faculty, Aix-Marseille University, Marseille, France (A.B., J.F., Z.B., M.B., A.J.); I2M-UMR CNRS 7373, Aix-Marseille University, Centrale Marseille, Marseille, France (J.F., B.G.); ImVia Laboratory and University Hospital of Dijon, Bourgogne-Franche Comté University, Dijon, France (A.L.); Department of Radiology, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France (L.B.); Department of Cardiovascular Imaging, Lille University Hospital, Lille, France (F.P.); and Department of Diagnostic Imaging, Rouen University Hospital, Rouen, France (J.N.D.)
| | - François Pontana
- Departments of Radiology (A.B., A.J.) and Cardiology (G.H.), Hôpital de la Timone Adultes, AP-HM, 264, rue Saint-Pierre 13385 Marseille Cedex 05, France; CRMBM-UMR CNRS 7339, Medical Faculty, Aix-Marseille University, Marseille, France (A.B., J.F., Z.B., M.B., A.J.); I2M-UMR CNRS 7373, Aix-Marseille University, Centrale Marseille, Marseille, France (J.F., B.G.); ImVia Laboratory and University Hospital of Dijon, Bourgogne-Franche Comté University, Dijon, France (A.L.); Department of Radiology, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France (L.B.); Department of Cardiovascular Imaging, Lille University Hospital, Lille, France (F.P.); and Department of Diagnostic Imaging, Rouen University Hospital, Rouen, France (J.N.D.)
| | - Jean-Nicolas Dacher
- Departments of Radiology (A.B., A.J.) and Cardiology (G.H.), Hôpital de la Timone Adultes, AP-HM, 264, rue Saint-Pierre 13385 Marseille Cedex 05, France; CRMBM-UMR CNRS 7339, Medical Faculty, Aix-Marseille University, Marseille, France (A.B., J.F., Z.B., M.B., A.J.); I2M-UMR CNRS 7373, Aix-Marseille University, Centrale Marseille, Marseille, France (J.F., B.G.); ImVia Laboratory and University Hospital of Dijon, Bourgogne-Franche Comté University, Dijon, France (A.L.); Department of Radiology, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France (L.B.); Department of Cardiovascular Imaging, Lille University Hospital, Lille, France (F.P.); and Department of Diagnostic Imaging, Rouen University Hospital, Rouen, France (J.N.D.)
| | - Badih Ghattas
- Departments of Radiology (A.B., A.J.) and Cardiology (G.H.), Hôpital de la Timone Adultes, AP-HM, 264, rue Saint-Pierre 13385 Marseille Cedex 05, France; CRMBM-UMR CNRS 7339, Medical Faculty, Aix-Marseille University, Marseille, France (A.B., J.F., Z.B., M.B., A.J.); I2M-UMR CNRS 7373, Aix-Marseille University, Centrale Marseille, Marseille, France (J.F., B.G.); ImVia Laboratory and University Hospital of Dijon, Bourgogne-Franche Comté University, Dijon, France (A.L.); Department of Radiology, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France (L.B.); Department of Cardiovascular Imaging, Lille University Hospital, Lille, France (F.P.); and Department of Diagnostic Imaging, Rouen University Hospital, Rouen, France (J.N.D.)
| | - Alexis Jacquier
- Departments of Radiology (A.B., A.J.) and Cardiology (G.H.), Hôpital de la Timone Adultes, AP-HM, 264, rue Saint-Pierre 13385 Marseille Cedex 05, France; CRMBM-UMR CNRS 7339, Medical Faculty, Aix-Marseille University, Marseille, France (A.B., J.F., Z.B., M.B., A.J.); I2M-UMR CNRS 7373, Aix-Marseille University, Centrale Marseille, Marseille, France (J.F., B.G.); ImVia Laboratory and University Hospital of Dijon, Bourgogne-Franche Comté University, Dijon, France (A.L.); Department of Radiology, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France (L.B.); Department of Cardiovascular Imaging, Lille University Hospital, Lille, France (F.P.); and Department of Diagnostic Imaging, Rouen University Hospital, Rouen, France (J.N.D.)
| |
Collapse
|
7
|
Kulikova OV, Myasnikov RP, Mershina EA, Pilus PS, Koretskiy SN, Meshkov AN, Kiseleva AV, Kharlap MS, Sinitsyn VE, Sdvigova NA, Gandaeva LA, Barskiy VI, Derevnina YV, Zharova OP, Basargina EN, Boytsov SA, Drapkina OM. Familial left ventricular noncompaction: phenotypes and clinical course. Results of the multicenter registry. TERAPEVT ARKH 2021; 93:381-388. [DOI: 10.26442/00403660.2021.04.200677] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2021] [Accepted: 06/01/2021] [Indexed: 11/22/2022]
Abstract
Aim. To analyze and demonstrate various phenotypes in patients with familial left ventricular noncompaction (LVNC).
Materials and methods. In 2013 was created a multicenter registry of LVNC patients. On its basis 30 families with a familial LVNC were selected.
Results. 30 LVNC families were selected from the register. From a total of 115 people (probands and relatives) in 71 (61.7%) LVNC was diagnosed (30 probands and 41 relatives with non-compact myocardial criteria). The most common type of remodeling in patients was the dilated type (DT) (n=30), the isolated LVNC with preserved ejection fraction (EF) was slightly less common (n=23), and the hypertrophic type (GT) was detected in 8 patients. 4 patients were diagnosed with the isolated LVNC with a reduced EF. 3 patients were with a combination of non-compact myocardium with congenital heart disease and with a combination of DT and GT (DT+GT). During the analysis of cases a combination of different phenotypes in the same family was observed. The largest number of families was diagnosed with a combination of DT and the isolated LVNC with preserved EF. The development of cardiovascular complications was associated with DT.
Conclusion. Family cases of LVNC had different types of myocardial remodeling and variants of clinical course. In one family a combination of different types of left ventricular remodeling is possible. DT is associated with the most severe clinical manifestations. The clinical picture of the isolated LVNC with preserved EF, is the most favorable, but in rare cases, serious clinical manifestations were observed.
Collapse
|
8
|
Rohde S, Muslem R, Kaya E, Dalinghaus M, van Waning JI, Majoor-Krakauer D, Towbin J, Caliskan K. State-of-the art review: Noncompaction cardiomyopathy in pediatric patients. Heart Fail Rev 2021; 27:15-28. [PMID: 33715140 PMCID: PMC8739285 DOI: 10.1007/s10741-021-10089-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 02/15/2021] [Indexed: 12/13/2022]
Abstract
Noncompaction cardiomyopathy (NCCM) is a disease characterized by hypertrabeculation, commonly hypothesized due to an arrest in compaction during fetal development. In 2006, NCCM was classified as a distinct form of cardiomyopathy (CMP) by the American Heart Association. NCCM in childhood is more frequently familial than when diagnosed in adulthood and is associated with other congenital heart diseases (CHDs), other genetic CMPs, and neuromuscular diseases (NMDs). It is yet a rare cardiac diseased with an estimated incidence of 0.12 per 100.000 in children up to 10 years of age. Diagnosing NCCM can be challenging due to non-uniform diagnostic criteria, unawareness, presumed other CMPs, and presence of CHD. Therefore, the incidence of NCCM in children might be an underestimation. Nonetheless, NCCM is the third most common cardiomyopathy in childhood and is associated with heart failure, arrhythmias, and/or thromboembolic events. This state-of-the-art review provides an overview on pediatric NCCM. In addition, we discuss the natural history, epidemiology, genetics, clinical presentation, outcome, and therapeutic options of NCCM in pediatric patients, including fetuses, neonates, infants, and children. Furthermore, we provide a simple classification of different forms of the disease. Finally, the differences between the pediatric population and the adult population are described.
Collapse
Affiliation(s)
- Sofie Rohde
- Thoraxcenter, Department of Cardiology, Erasmus University Medical Center, Room RG 431, 3015 GD, Rotterdam, The Netherlands
| | - Rahatullah Muslem
- Thoraxcenter, Department of Cardiology, Erasmus University Medical Center, Room RG 431, 3015 GD, Rotterdam, The Netherlands
| | - Emrah Kaya
- Thoraxcenter, Department of Cardiology, Erasmus University Medical Center, Room RG 431, 3015 GD, Rotterdam, The Netherlands
| | - Michel Dalinghaus
- Division of Pediatric Cardiology, Sophia Children's Hospital, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Jaap I van Waning
- Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands
| | | | - Jeffery Towbin
- The Heart Institute, Le Bonheur Children's Hospital, Memphis, TN, USA
| | - Kadir Caliskan
- Thoraxcenter, Department of Cardiology, Erasmus University Medical Center, Room RG 431, 3015 GD, Rotterdam, The Netherlands.
| |
Collapse
|
9
|
Fonseca AC, Almeida AG, Santos MO, Ferro JM. Neurological complications of cardiomyopathies. HANDBOOK OF CLINICAL NEUROLOGY 2021; 177:91-109. [PMID: 33632460 DOI: 10.1016/b978-0-12-819814-8.00001-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/28/2023]
Abstract
There is a multifaceted relationship between the cardiomyopathies and a wide spectrum of neurological disorders. Severe acute neurological events, such as a status epilepticus and aneurysmal subarachnoid hemorrhage, may result in an acute cardiomyopathy the likes of Takotsubo cardiomyopathy. Conversely, the cardiomyopathies may result in a wide array of neurological disorders. Diagnosis of a cardiomyopathy may have already been established at the time of the index neurological event, or the neurological event may have prompted subsequent cardiac investigations, which ultimately lead to the diagnosis of a cardiomyopathy. The cardiomyopathies belong to one of the many phenotypes of complex genetic diseases or syndromes, which may also involve the central or peripheral nervous systems. A number of exogenous agents or risk factors such as diphtheria, alcohol, and several viruses may result in secondary cardiomyopathies accompanied by several neurological manifestations. A variety of neuromuscular disorders, such as myotonic dystrophy or amyloidosis, may demonstrate cardiac involvement during their clinical course. Furthermore, a number of genetic cardiomyopathies phenotypically incorporate during their clinical evolution, a gamut of neurological manifestations, usually neuromuscular in nature. Likewise, neurological complications may be the result of diagnostic procedures or medications for the cardiomyopathies and vice versa. Neurological manifestations of the cardiomyopathies are broad and include, among others, transient ischemic attacks, ischemic strokes, intracranial hemorrhages, syncope, muscle weakness and atrophy, myotonia, cramps, ataxia, seizures, intellectual developmental disorder, cognitive impairment, dementia, oculomotor palsies, deafness, retinal involvement, and headaches.
Collapse
Affiliation(s)
- Ana Catarina Fonseca
- Neurology Service, Hospital Santa Maria, Centro Hospitalar Lisboa Norte and Faculty of Medicine, University of Lisbon, Lisbon, Portugal
| | - Ana G Almeida
- Cardiology Service, Hospital Santa Maria, Centro Hospitalar Lisboa Norte and Faculty of Medicine, University of Lisbon, Lisbon, Portugal
| | - Miguel Oliveira Santos
- Neurology Service, Hospital Santa Maria, Centro Hospitalar Lisboa Norte and Faculty of Medicine, University of Lisbon, Lisbon, Portugal
| | - José M Ferro
- Neurology Service, Hospital Santa Maria, Centro Hospitalar Lisboa Norte and Faculty of Medicine, University of Lisbon, Lisbon, Portugal.
| |
Collapse
|
10
|
Do children with left ventricular noncompaction and a noncompaction-to-compaction ratio < 2 have a better prognosis? BMC Pediatr 2020; 20:430. [PMID: 32907541 PMCID: PMC7488020 DOI: 10.1186/s12887-020-02312-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/05/2019] [Accepted: 08/24/2020] [Indexed: 11/10/2022] Open
Abstract
Background Ultrasonography is commonly used to diagnose left ventricular noncompaction (LVNC). A ratio of noncompacted to compacted myocardium (NC/C ratio) > >2 is often used to diagnose LVNC. However, a large proportion of patients with noncompact myocardium have NC/C < 2, and the prognosis of these patients have not been studied. Methods We included children diagnosed with LVNC between 0 and 15 years of age from January 2007 to December 2018. LVNC was diagnosed based on Stöllberger standard when over three trabeculae were found to be associated with the interventricular recesses. A maximal end systolic ratio of noncompacted to compacted layers was NC/C ratio. Outcomes for LVNC subjects with NC/C < 2 and NC/C > 2 were compared using Kaplan-Meier methods. Results There were 124 newly diagnosed LVNC cases, classified as isolated (i-LVNC, n = 47) or non-isolated (ni-LVNC, n = 77) LVNC and NC/C > 2 (n = 43) or < 2 (n = 81). The median (interquartile range) follow-up duration was 12 (3–30) months for all patients and 16 (6–36) months for survivors. Sixteen patients with i-LVNC died during follow-up. Patients with i-LVNC and NC/C > 2 had worse survival than those with NC/C < 2 (p = 0.022). Conclusions In conclusion, during a 12-month follow-up, patients with i-LVNC with NC/C < 2 had a benign prognosis and better outcomes than those with NC/C > 2, suggesting that the former could have a more active and routine lifestyle.
Collapse
|
11
|
Stöllberger C, Hasun M, Winkler-Dworak M, Finsterer J. Usefulness of Neuromuscular Co-morbidity, Left Bundle Branch Block, and Atrial Fibrillation to Predict the Long-Term Prognosis of Left Ventricular Hypertrabeculation/Noncompaction. Am J Cardiol 2020; 128:168-173. [PMID: 32650915 DOI: 10.1016/j.amjcard.2020.04.040] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/10/2020] [Revised: 04/22/2020] [Accepted: 04/27/2020] [Indexed: 02/01/2023]
Abstract
The prognosis of patients with left ventricular hypertrabeculation/noncompaction (LVHT) is assessed controversially. LVHT is associated with other cardiac abnormalities and with neuromuscular disorders (NMD). Aim of the study was to assess cardiac and neurological findings as predictors of mortality rate in adult LVHT-patients. Included were patients with LVHT diagnosed between 1995 and 2019 in 1 echocardiographic laboratory. Patients underwent a baseline cardiologic examination and were invited for a neurological investigation. In January 2020, their survival status was assessed. End points were death or heart transplantation. LVHT was diagnosed by echocardiography in 310 patients (93 female, aged 53 ± 18 years) with a prevalence of 0.4%/year. A neurologic investigation was performed in 205 patients (67%). A specific NMD was found in 33 (16%), NMD of unknown etiology in 123 (60%) and the neurological investigation was normal in 49 (24%) patients. During follow-up of 84 ± 71 months, 59 patients received electronic devices, 105 patients died, and 6 underwent heart transplantation. The mortality was 4.7%/year, the rate of heart transplantation/death 5%/year. By multivariate analysis, the following parameters were identified to elevate the risk of mortality/heart transplantation: increased age (p = 0.005), inpatient (p = 0.001), presence of a specific NMD (p = 0.0312) or NMD of unknown etiology (p = 0.0365), atrial fibrillation (p = 0.0000), ventricular premature complexes (p = 0.0053), exertional dyspnea (p = 0.0023), left bundle branch block (p = 0.0201), and LVHT of the posterior wall (p = 0.0158). In conclusion, LVHT patients should be systematically investigated neurologically since neurological co-morbidity has a prognostic impact.
Collapse
Affiliation(s)
| | | | - Maria Winkler-Dworak
- Vienna Institute of Demography of the Austrian Academy of Sciences, Wittgenstein Centre for Demography and Global Human Capital, Wien, Austria
| | | |
Collapse
|
12
|
Stöllberger C, Finsterer J. Unravel the genetic background of noncompaction before relating it with myocardial hypoperfusion. ESC Heart Fail 2020; 7:1997-1998. [PMID: 32436634 PMCID: PMC7373935 DOI: 10.1002/ehf2.12753] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2020] [Accepted: 04/20/2020] [Indexed: 12/14/2022] Open
|
13
|
Aung N, Doimo S, Ricci F, Sanghvi MM, Pedrosa C, Woodbridge SP, Al-Balah A, Zemrak F, Khanji MY, Munroe PB, Naci H, Petersen SE. Prognostic Significance of Left Ventricular Noncompaction: Systematic Review and Meta-Analysis of Observational Studies. Circ Cardiovasc Imaging 2020; 13:e009712. [PMID: 31959004 PMCID: PMC7012350 DOI: 10.1161/circimaging.119.009712] [Citation(s) in RCA: 59] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/21/2019] [Accepted: 11/27/2019] [Indexed: 12/12/2022]
Abstract
BACKGROUND Although left ventricular noncompaction (LVNC) has been associated with an increased risk of adverse cardiovascular events, the accurate incidence of cardiovascular morbidity and mortality is unknown. We, therefore, aimed to assess the incidence rate of LVNC-related cardiovascular events. METHODS We systematically searched observational studies reporting the adverse outcomes related to LVNC. The primary end point was cardiovascular mortality. RESULTS We identified 28 eligible studies enrolling 2501 LVNC patients (mean age, 46 years; male/female ratio, 1.7). After a median follow-up of 2.9 years, the pooled event rate for cardiovascular mortality was 1.92 (95% CI, 1.54-2.30) per 100 person-years. LVNC patients had a similar risk of cardiovascular mortality compared with a dilated cardiomyopathy control group (odds ratio, 1.10 [95% CI, 0.18-6.67]). The incidence rates of all-cause mortality, stroke and systemic emboli, heart failure admission, cardiac transplantation, ventricular arrhythmias, and cardiac device implantation were 2.16, 1.54, 3.53, 1.24, 2.17, and 2.66, respectively, per 100 person-years. Meta-regression and subgroup analyses revealed that left ventricular ejection fraction, not the extent of left ventricular trabeculation, had an important influence on the variability of incidence rates. The risks of thromboembolism and ventricular arrhythmias in LVNC patients were similar to dilated cardiomyopathy patients. However, LVNC patients had a higher incidence of heart failure hospitalization than dilated cardiomyopathy patients. CONCLUSIONS Patients with LVNC carry a similar cardiovascular risk when compared with dilated cardiomyopathy patients. Left ventricular ejection fraction-a conventional indicator of heart failure severity, not the extent of trabeculation-appears to be an important determinant of adverse outcomes in LVNC patients. Registration: https://www.crd.york.ac.uk/PROSPERO/ Unique identifier: CRD42018096313.
Collapse
Affiliation(s)
- Nay Aung
- William Harvey Research Institute, NIHR Cardiovascular Biomedical Research Centre at Barts, Queen Mary University of London, Charterhouse Square, United Kingdom (N.A., M.M.S., C.P., S.P.W., F.Z., M.Y.K., P.B.M., S.E.P.)
- Barts Heart Centre, St Bartholomew’s Hospital, Barts Health NHS Trust, West Smithfield, London, United Kingdom (N.A., M.M.S., F.Z., M.Y.K., P.B.M., S.E.P.)
| | - Sara Doimo
- Cardiovascular Department, Azienda Sanitaria Universitaria Integrata, University of Trieste, Italy (S.D.)
| | - Fabrizio Ricci
- Department of Neuroscience, Imaging and Clinical Sciences, Institute of Advanced Biomedical Technologies, “G. d’Annunzio” University, Chieti, Italy (F.R.)
| | - Mihir M. Sanghvi
- William Harvey Research Institute, NIHR Cardiovascular Biomedical Research Centre at Barts, Queen Mary University of London, Charterhouse Square, United Kingdom (N.A., M.M.S., C.P., S.P.W., F.Z., M.Y.K., P.B.M., S.E.P.)
- Barts Heart Centre, St Bartholomew’s Hospital, Barts Health NHS Trust, West Smithfield, London, United Kingdom (N.A., M.M.S., F.Z., M.Y.K., P.B.M., S.E.P.)
| | - Cesar Pedrosa
- William Harvey Research Institute, NIHR Cardiovascular Biomedical Research Centre at Barts, Queen Mary University of London, Charterhouse Square, United Kingdom (N.A., M.M.S., C.P., S.P.W., F.Z., M.Y.K., P.B.M., S.E.P.)
| | - Simon P. Woodbridge
- William Harvey Research Institute, NIHR Cardiovascular Biomedical Research Centre at Barts, Queen Mary University of London, Charterhouse Square, United Kingdom (N.A., M.M.S., C.P., S.P.W., F.Z., M.Y.K., P.B.M., S.E.P.)
| | - Amer Al-Balah
- Imperial College London, Kensington, United Kingdom (A.A.-B.)
| | - Filip Zemrak
- William Harvey Research Institute, NIHR Cardiovascular Biomedical Research Centre at Barts, Queen Mary University of London, Charterhouse Square, United Kingdom (N.A., M.M.S., C.P., S.P.W., F.Z., M.Y.K., P.B.M., S.E.P.)
- Barts Heart Centre, St Bartholomew’s Hospital, Barts Health NHS Trust, West Smithfield, London, United Kingdom (N.A., M.M.S., F.Z., M.Y.K., P.B.M., S.E.P.)
| | - Mohammed Y. Khanji
- William Harvey Research Institute, NIHR Cardiovascular Biomedical Research Centre at Barts, Queen Mary University of London, Charterhouse Square, United Kingdom (N.A., M.M.S., C.P., S.P.W., F.Z., M.Y.K., P.B.M., S.E.P.)
- Barts Heart Centre, St Bartholomew’s Hospital, Barts Health NHS Trust, West Smithfield, London, United Kingdom (N.A., M.M.S., F.Z., M.Y.K., P.B.M., S.E.P.)
| | - Patricia B. Munroe
- William Harvey Research Institute, NIHR Cardiovascular Biomedical Research Centre at Barts, Queen Mary University of London, Charterhouse Square, United Kingdom (N.A., M.M.S., C.P., S.P.W., F.Z., M.Y.K., P.B.M., S.E.P.)
- Barts Heart Centre, St Bartholomew’s Hospital, Barts Health NHS Trust, West Smithfield, London, United Kingdom (N.A., M.M.S., F.Z., M.Y.K., P.B.M., S.E.P.)
- Clinical Pharmacology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom (P.B.M.)
| | - Huseyin Naci
- Department of Health Policy, London School of Economics and Political Science, United Kingdom (H.N.)
| | - Steffen E. Petersen
- William Harvey Research Institute, NIHR Cardiovascular Biomedical Research Centre at Barts, Queen Mary University of London, Charterhouse Square, United Kingdom (N.A., M.M.S., C.P., S.P.W., F.Z., M.Y.K., P.B.M., S.E.P.)
- Barts Heart Centre, St Bartholomew’s Hospital, Barts Health NHS Trust, West Smithfield, London, United Kingdom (N.A., M.M.S., F.Z., M.Y.K., P.B.M., S.E.P.)
| |
Collapse
|
14
|
Peter AK, Rossi AC, Buvoli M, Ozeroff CD, Crocini C, Perry AR, Buvoli AE, Lee LA, Leinwand LA. Expression of Normally Repressed Myosin Heavy Chain 7b in the Mammalian Heart Induces Dilated Cardiomyopathy. J Am Heart Assoc 2019; 8:e013318. [PMID: 31364453 PMCID: PMC6761648 DOI: 10.1161/jaha.119.013318] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Background In mammals, muscle contraction is controlled by a family of 10 sarcomeric myosin motors. The expression of one of its members, MYH7b, is regulated by alternative splicing, and while the protein is restricted to specialized muscles such as extraocular muscles or muscle spindles, RNA that cannot encode protein is expressed in most skeletal muscles and in the heart. Remarkably, birds and snakes express MYH7b protein in both heart and skeletal muscles. This observation suggests that in the mammalian heart, the motor activity of MYH7b may only be needed during development since its expression is prevented in adult tissue, possibly because it could promote disease by unbalancing myocardial contractility. Methods and Results We have analyzed MYH7b null mice to determine the potential role of MYH7b during cardiac development and also generated transgenic mice with cardiac myocyte expression of MYH7b protein to measure its impact on cardiomyocyte function and contractility. We found that MYH7b null mice are born at expected Mendelian ratios and do not have a baseline cardiac phenotype as adults. In contrast, transgenic cardiac MYH7b protein expression induced early cardiac dilation in males with significantly increased left ventricular mass in both sexes. Cardiac dilation is progressive, leading to early cardiac dysfunction in males, but later dysfunction in females. Conclusions The data presented show that the expression of MYH7b protein in the mammalian heart has been inhibited during the evolution of mammals most likely to prevent the development of a severe cardiomyopathy that is sexually dimorphic.
Collapse
Affiliation(s)
- Angela K Peter
- Department of Molecular, Cellular and Developmental Biology Biofrontiers Institute University of Colorado Boulder CO
| | - Alberto C Rossi
- Department of Molecular, Cellular and Developmental Biology Biofrontiers Institute University of Colorado Boulder CO
| | - Massimo Buvoli
- Department of Molecular, Cellular and Developmental Biology Biofrontiers Institute University of Colorado Boulder CO
| | - Christopher D Ozeroff
- Department of Molecular, Cellular and Developmental Biology Biofrontiers Institute University of Colorado Boulder CO
| | - Claudia Crocini
- Department of Molecular, Cellular and Developmental Biology Biofrontiers Institute University of Colorado Boulder CO
| | - Amy R Perry
- Department of Molecular, Cellular and Developmental Biology Biofrontiers Institute University of Colorado Boulder CO
| | - Ada E Buvoli
- Department of Molecular, Cellular and Developmental Biology Biofrontiers Institute University of Colorado Boulder CO
| | - Lindsey A Lee
- Department of Molecular, Cellular and Developmental Biology Biofrontiers Institute University of Colorado Boulder CO
| | - Leslie A Leinwand
- Department of Molecular, Cellular and Developmental Biology Biofrontiers Institute University of Colorado Boulder CO
| |
Collapse
|
15
|
Clinical and genetic insights into non-compaction: a meta-analysis and systematic review on 7598 individuals. Clin Res Cardiol 2019; 108:1297-1308. [PMID: 30980206 DOI: 10.1007/s00392-019-01465-3] [Citation(s) in RCA: 48] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/31/2019] [Accepted: 03/19/2019] [Indexed: 10/27/2022]
Abstract
BACKGROUND Left ventricular non-compaction has been increasingly diagnosed in recent years. However, it is still debated whether non-compaction is a pathological condition or a physiological trait. In this meta-analysis and systematic review, we compare studies, which investigated these two different perspectives. Furthermore, we provide a comprehensive overview on the clinical outcome as well as genetic background of left ventricular non-compaction cardiomyopathy in adult patients. METHODS AND RESULTS We retrieved PubMed/Medline literatures in English language from 2000 to 19/09/2018 on clinical outcome and genotype of patients with non-compaction. We summarized and extensively reviewed all studies that passed selection criteria and performed a meta-analysis on key phenotypic parameters. Altogether, 35 studies with 2271 non-compaction patients were included in our meta-analysis. The mean age at diagnosis was the mid of their fifth decade. Two-thirds of patients were male. Congenital heart diseases including atrial or ventricular septum defect or Ebstein anomaly were reported in 7% of patients. Twenty-four percent presented with family history of cardiomyopathy. The mean frequency of neuromuscular diseases was 5%. Heart rhythm abnormalities were reported frequently: conduction disease in 26%, supraventricular tachycardia in 17%, and sustained or non-sustained ventricular tachycardia in 18% of patients. Three important outcome measures were reported including systemic thromboembolic events with a mean frequency of 9%, heart transplantation with 4%, and adequate ICD therapy with 15%. Nine studies investigated the genetics of non-compaction cardiomyopathy. The most frequently mutated gene was TTN with a pooled frequency of 11%. The average frequency of MYH7 mutations was 9%, for MYBPC3 mutations 5%, and for CASQ2 and LDB3 3% each. TPM1, MIB1, ACTC1, and LMNA mutations had an average frequency of 2% each. Mutations in PLN, HCN4, TAZ, DTNA, TNNT2, and RBM20 were reported with a frequency of 1% each. We also summarized the results of eight studies investigating the non-compaction in altogether 5327 athletes, pregnant women, patients with sickle cell disease, as well as individuals from population-based cohorts, in which the presence of left ventricular hypertrabeculation ranged from 1.3 to 37%. CONCLUSION The summarized data indicate that non-compaction may lead to unfavorable outcome in different cardiomyopathy entities. The presence of key features in a multimodal diagnostic approach could distinguish between benign morphological trait and manifest cardiomyopathy.
Collapse
|
16
|
Malli N, Wilfinger-Lutz N, Krugluger W, Stöllberger C, Winkler-Dwora K M, Finsterer J. Prognostic role of Pro-BNP levels in left ventricular hypertrabeculation/non-compaction and neuromuscular disorders: results of a pilot study. Minerva Cardioangiol 2019; 67:254-256. [PMID: 30919605 DOI: 10.23736/s0026-4725.19.04908-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Norbert Malli
- Second Medical Department, K.A. Rudolfstiftung, Vienna, Austria
| | | | | | | | | | | |
Collapse
|
17
|
Stöllberger C, Finsterer J. Understanding left ventricular hypertrabeculation/noncompaction: pathomorphologic findings and prognostic impact of neuromuscular comorbidities. Expert Rev Cardiovasc Ther 2018; 17:95-109. [PMID: 30570401 DOI: 10.1080/14779072.2019.1561280] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
INTRODUCTION When >3 trabeculations associated with interventricular recesses are found, this is termed 'left ventricular hypertrabeculation/noncompaction' (LVHT). Cardiac-imaging methods detect LVHT in all ages, isolated or associated with extracardiac, especially neuromuscular disorders (NMDs). Many issues about LVHT are unclear. The review gives an update about pathomorphologic findings in patients >14 years and the role of NMDs in LVHT. Areas covered: A PubMed-search for the terms "noncompaction" or "non-compaction" or "hypertrabeculation" AND "autopsy" or 'biopsy' or 'ultrastructure' or 'electron microscopy' AND 'neuromuscular' or 'myopathy' or 'neuropathy' was carried out from 1985 to July 2018. Expert commentary: Macroanatomic (n = 65), histopathologic (n = 59) and ultrastructural (n = 7) reports were found. A comparison with echocardiography was described in 45 cases. Measurements of non-compacted and compacted layer were only given from hearts investigated in short-axis cuts after formaldehyde-fixation. Endocardial, subendocardial and interstitial fibrosis were frequent findings. When LVHT-patients were systematically investigated, a NMD was found in 80%, most frequently mitochondrial disorders, Barth syndrome, zaspopathy, and myotonic dystrophy type 1. LVHT does not seem to be a special type of cardiac involvement of NMDs. NMDs affect prognosis in LVHT as well as LVHT affects prognosis in patients with Duchenne muscular dystrophy.
Collapse
Affiliation(s)
- Claudia Stöllberger
- a 2nd Medical Department with Cardiology and Intensive Care Medicine , Rudolfstifung Hospital , Vienna , Austria
| | - Josef Finsterer
- b Rudolfstiftung Hospital , Danube University Krems , Vienna , Austria
| |
Collapse
|